Previous Page
What is INQOVI?
Next Page
Efficacy & Safety
Who is appropriate for oral INQOVI?
INQOVI is appropriate for treatment-naïve and previously treated adult patients with intermediate- to high-risk MDS, including CMML.1
Start with INQOVI
Consider INQOVI for your adult patients like Gregory, newly diagnosed with high-risk MDS
Actor portrayal.
Patient Profile:
Gregory, 71, treatment-naïve
Diagnosis
- Diagnosed with high-risk MDS when a blood examination revealed pancytopenia
- Bone marrow biopsy indicated 10% blasts and multilineage dysplasia
Blood Test Results
- Hemoglobin: 6.0 g/dL
- Red blood cells: 4.1 M/µL
- White blood cells: 3.0 K/µL
- ANC: 570 cells/µL; bands: 3%
- IPSS-R Score of 5.5 points=high
- Platelets: 76 x 109/L
- Neutrophils: 16%
- Cytogenetic category: Good
About Gregory
- He enjoys fishing and outdoor activities with his wife and 2 grandchildren
- He is transfusion dependent
- His treatment team discussed hypomethylating agents due to his IPSS-R Score, but Gregory does not require a port placement
- He would prefer a treatment option that he can take in the convenience of his home
- ECOG performance status was 1 prior to taking INQOVI
Switch to INQOVI
Consider INQOVI for your adult patients like Diane, previously treated with IV HMA therapy for intermediate-risk MDS
Actor portrayal.
Patient Profile:
Diane, 74, treatment-switch, 6 cycles of IV decitabine
Diagnosis
- Diagnosed 6 months ago with intermediate-risk MDS
- Tests revealed moderate anemia, neutropenia; there was a prior diagnosis of renal disease
- 11.2% blasts
- Initiated MDS treatment with IV HMA therapy
- Began transfusion for anemia and monitored progress
- Has since achieved transfusion independence and is stable
Blood Test Results
- Hemoglobin: 6.5 g/dL
- Red blood cells: 3.6 M/µL
- White blood cells: 4.0 K/µL
- ANC: 800 cells/µL; bands: 2%
- IPSS-R Score of 4.5 points=intermediate
- Platelets: 103 x 109/L
- Neutrophils: 18%
- Cytogenetic category: Very good
About Diane
- She does not have a full-time caregiver or family member to help with travel; she has been unable to get to the infusion center to complete her most recent cycle
- She needed a treatment option she could take at home
- ECOG performance status of 2 prior to beginning INQOVI
Learn more about INQOVI from this panel discussion
View a panel discussion between a well-respected hematologist-oncologist, nurse practitioner, and patient caregiver advocate on the topic of myelodysplastic syndromes treatment at home—including the advantages and disadvantages of current treatment options, patient care, and INQOVI.
Additional Information
Your patients who may be appropriate for INQOVI1
- Diagnosed with de novo or secondary MDS, including CMML
- Classified as intermediate- or high-risk MDS
- Are treatment naïve
- Have previously been treated and may be ready to switch from current treatment
Additional Patient Considerations1,2:
- Wish to take their HMA therapy in the comfort of their own home
- Unable to have, or do not wish to have, infusion port placement
- Cannot manage travel to the infusion center
ANC=absolute neutrophil count; CMML=chronic myelomonocytic leukemia; ECOG=Eastern Cooperative Oncology Group; HMA=hypomethylating agent; IPSS-R=Revised International Prognostic Scoring System; MDS=myelodysplastic syndromes.
References: 1. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022. 2. Savona MR, Odenike O, Amrein PC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6(4):e194-e203.